stockrow
Friday 6 November 2026
Export TIL’s income statement to Excel — free account
Instil Bio, Inc.
- EPS
- +80.6%
- Free cash flow
- +68.6%
- Total debt
- +0.91%
Quarter to June 2026, against a year earlier
6.85
0.14
−2.00%
Follow TIL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | — | — | — | — | — | 0 | — | 2 | — | — | — | |
| Gross margin, % | — | — | — | 0.00 | 100.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (7) | (38) | (157) | (225) | (156) | (74) | (71) | (30) | +49.0% | ||||||
| EBT margin, % | — | — | — | 0.00 | (27,236.96) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (7) | (38) | (157) | (223) | (156) | (74) | (71) | (30) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (11.01) | (47.18) | (29.60) | (34.40) | (24.00) | (11.39) | (10.70) | (4.47) | (0.5%) | ||||||
| Cash flow | — | — | — | (8.93) | (37.02) | (23.05) | (27.82) | (12.61) | (8.56) | (5.49) | (3.48) | (7.8%) | ||||||
| Capex | — | — | — | (0.35) | (63.53) | (10.91) | (13.06) | (3.18) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (9.29) | (100.55) | (33.96) | (40.88) | (15.79) | (8.56) | (5.49) | (3.48) | (8.4%) | ||||||
| Book value | — | — | — | (11.63) | (49.50) | 104.76 | 56.15 | 34.72 | 26.03 | 17.08 | 15.83 | n/m | ||||||
| Shares, m | — | — | — | 1 | 1 | 5 | 6 | 7 | 7 | 7 | 7 | +49.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | 3,065.12 | — | — | — | — | — | 336.64 | — | ||||||
| P/B | — | — | — | — | 0.00 | — | — | — | — | — | 0.43 | — | ||||||
| EV/Sales | — | — | — | — | 1,313.57 | — | — | — | — | — | 447.22 | — | ||||||
| EV/FCF | — | — | — | — | (2.25) | — | — | — | — | — | (1.39) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (5) | (30) | (122) | (180) | (82) | (56) | (37) | (24) | +38.0% | |||||
| Capex | — | — | — | 0 | (51) | (58) | (85) | (21) | — | — | (21) | +215.0% | ||||||
| Free cash flow | — | — | — | (6) | (80) | (180) | (265) | (103) | (56) | (37) | (24) | +37.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 8 | 233 | 423 | 237 | 150 | 117 | 187 | 68 | +69.5% | |||||
| Net debt | — | — | — | (9) | (242) | (454) | (189) | (70) | (31) | 9 | 15 | n/m | ||||||
| Shareholders’ equity | — | — | — | (7) | (40) | 555 | 364 | 226 | 169 | 114 | 107 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (137.65) | (22.98) | (33.76) | (40.87) | (38.65) | (25.16) | (30.56) | (14.13) | +107.1 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (96.17) | (80.86) | (64.02) | (33.19) | (40.13) | (18.94) | (40.1) pt | ||||||
| ROE | — | — | — | 28.06 | 162.35 | (60.82) | (48.58) | (52.96) | (37.51) | (50.39) | (25.33) | (78.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 150 | 412 | 192 | 49 | 14 | 17 | — | (35.3%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2020 · latest quarter Sep 2020
Instil Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PLRX Pliant Therapeutics, Inc. | $50.5M | — (loss-making) | — (loss-making) | −95.03% (below 0%: shrinking) | n/m | +68.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HOWL Werewolf Therapeutics, Inc. | $49.6M | — (loss-making) | — (loss-making) | +256.11% (above 0%: growing) | n/m | +146.46% (above 0%: growing) | 100.00% | 34.09% | Compare |
| APLM Apollomics Inc. | $49.5M | — (loss-making) | — | — | 0.00% | +76.08% (above 0%: growing) | — | — | Compare |
| TIL Instil Bio, Inc. | $47.4M | — (loss-making) | — | — | n/m | +68.62% (above 0%: growing) | 0.00% | 0.00% | |
| IMA ImageneBio, Inc. | $47.3M | — (loss-making) | — (loss-making) | −60.08% (below 0%: shrinking) | n/m | +23.76% (above 0%: growing) | 100.00% | 0.00% | Compare |
| HYFT MindWalk Holdings Corp. | $47.1M | — (loss-making) | — (loss-making) | +19.37% (above 0%: growing) | n/m | +9.79% (above 0%: growing) | 58.58% | (159.86%) | Compare |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $46.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | Compare |
| MREO Mereo BioPharma Group plc - Sponsored ADR | $44.8M | — (loss-making) | — (loss-making) | — | n/m | +21.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IBIO iBio, Inc. | $44.4M | — (loss-making) | — (loss-making) | +100.00% (above 0%: growing) | n/m | −35.33% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $47.2M | — | — | +59.69% | — | +22.39% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 24 April 2026
Ownership
Directors and executive officers, together
47.00%
Bronson Crouch
36.70%
Curative Ventures V LLC
29.80%
BML Investment Partners, L.P.
9.50%
R. Kent McGaughy, Jr.
6.20%
Entity associated with CPMG, Inc.
6.10%
Sandeep Laumas, M.D.
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement